Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platinum-gemcitabine with or without nivolumab in first-line treatment of recurrent or metastatic nasopharyngeal carcinoma
KCT0006096Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab in nasopharyngeal carcinoma (NPC), sponsored by National Cancer Institute. Started Jul 2021; status: completed.
02
Drugs
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on KCT0006096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006096.